162. 類天疱瘡（後天性表皮水疱症を含む。）
［臨床試験数：70，薬物数：117（DrugBank：46），標的遺伝子数：30，標的パスウェイ数：128］
Searched query = "Pemphigoid", "Epidermolysis bullosa acquisita"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04128176 (ClinicalTrials.gov) | May 25, 2021 | 12/10/2019 | Efficacy and Safety of Rituximab Combined With Omalizumab in Patients With Bullous Pemphigoid | An Open-Label Study to Evaluate the Efficacy and Safety of Rituximab Combined With Omalizumab in Patients With Bullous Pemphigoid | Bullous Pemphigoid | Drug: Rituximab combined with Omalizumab | University of California, Davis | NULL | Not yet recruiting | 18 Years | 90 Years | All | 15 | Phase 3 | United States |
| 2 | NCT04540133 (ClinicalTrials.gov) | December 2020 | 28/8/2020 | Dexamethasone Solution and Dexamethasone in Mucolox™ | Dexamethasone Solution and Dexamethasone in Mucolox™ for the Treatment of Oral Inflammatory Ulcerative Diseases | Oral Lichen Planus;Mucous Membrane Pemphigoid;Pemphigus Vulgaris;Chronic Graft-versus-host-disease | Drug: dexamethasone 0.5mg/5ml solution;Drug: dexamethasone 0.5mg/5ml solution in Mucolox™ | University of California, San Francisco | NULL | Recruiting | 18 Years | N/A | All | 30 | Phase 2 | United States |
| 3 | NCT04612790 (ClinicalTrials.gov) | November 3, 2020 | 12/10/2020 | A Study to Investigate the Use of Benralizumab in Patients With Bullous Pemphigoid. | A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Investigate the Use of Benralizumab as a Treatment Option for Patients With Bullous Pemphigoid (FJORD) | Bullous Pemphigoid | Biological: Benralizumab;Biological: Placebo | AstraZeneca | NULL | Not yet recruiting | 18 Years | 130 Years | All | 120 | Phase 3 | United States;Bulgaria;Germany;Italy |
| 4 | NCT04206553 (ClinicalTrials.gov) | October 28, 2020 | 18/12/2019 | A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid | Bullous Pemphigoid | Drug: dupilumab;Drug: Matching Placebo;Drug: Oral corticosteroids (OCS) | Regeneron Pharmaceuticals | Sanofi | Recruiting | 18 Years | 90 Years | All | 98 | Phase 2;Phase 3 | United States;Australia;Germany;Japan |
| 5 | EUCTR2019-003520-20-DE (EUCTR) | 15/10/2020 | 26/03/2020 | A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients with Bullous Pemphigoid | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients with Bullous Pemphigoid - LIBERTY-BP ADEPT | Bullous pemphigoid (BP) MedDRA version: 20.0;Level: PT;Classification code 10034277;Term: Pemphigoid;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Trade Name: Dupixent Product Name: dupilumab INN or Proposed INN: dupilumab Other descriptive name: DUPILUMAB | Regeneron Pharmaceuticals, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 98 | Phase 2;Phase 3 | United States;France;Australia;Germany;Japan | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | NCT04563923 (ClinicalTrials.gov) | October 10, 2020 | 17/9/2020 | Treatment of Bullous Pemphigoid With Avdoralimab (IPH5401), an Anti-C5aR1 Monoclonal Antibody | Treatment of Bullous Pemphigoid With Avdoralimab (IPH5401), an Anti-C5aR1 Monoclonal Antibody | Bullous Pemphigoid | Drug: Avdoralimab (IPH5401);Other: Control | Centre Hospitalier Universitaire de Nice | NULL | Recruiting | 18 Years | N/A | All | 40 | Phase 2 | France |
| 7 | NCT04465292 (ClinicalTrials.gov) | September 1, 2020 | 14/5/2020 | The Effects of Tildrakizumab in Treatment of Bullous Pemphigoid | The Effects of Tildrakizumab in Treatment of Bullous Pemphigoid | Pemphigoid, Bullous | Drug: Tildrakizumab Prefilled Syringe | Brigham and Women's Hospital | Joseph Merola | Not yet recruiting | 18 Years | N/A | All | 16 | Early Phase 1 | NULL |
| 8 | EUCTR2020-002912-34-FR (EUCTR) | 11/08/2020 | 22/06/2020 | Treatment of bullous pemphigoid with avdoralimab (IPH5401), an anti-C5aR1 monoclonal antibody | Treatment of bullous pemphigoid with avdoralimab (IPH5401), an anti-C5aR1 monoclonal antibody - PB | Auto Immune bullous Diseases;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Product Name: avdoralimab Product Code: IPH5401 INN or Proposed INN: avdoralimab Other descriptive name: NNC0215-0384 | CHU NICE | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 40 | Phase 2 | France | ||
| 9 | EUCTR2019-003520-20-FR (EUCTR) | 19/05/2020 | 25/03/2020 | A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients with Bullous Pemphigoid | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients with Bullous Pemphigoid - LIBERTY-BP ADEPT | Bullous pemphigoid (BP) MedDRA version: 20.0;Level: PT;Classification code 10034277;Term: Pemphigoid;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Trade Name: Dupixent Product Name: dupilumab INN or Proposed INN: dupilumab Other descriptive name: DUPILUMAB | Regeneron Pharmaceuticals, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 80 | Phase 2;Phase 3 | United States;France;Spain;Australia;Germany;Japan | ||
| 10 | NCT04117932 (ClinicalTrials.gov) | March 11, 2020 | 4/10/2019 | Efficacy and Safety of Ustekinumab in Bullous Pemphigoid | Efficacy and Safety of Ustekinumab in Bullous Pemphigoid | Bullous Pemphigoid | Drug: Ustekinumab | CHU de Reims | NULL | Recruiting | 18 Years | 90 Years | All | 18 | Phase 2 | France |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 11 | NCT04499235 (ClinicalTrials.gov) | January 30, 2020 | 31/7/2020 | A Study to Assess the Therapeutic Effect and Safety of Adjunctive AKST4290 in Subjects With Bullous Pemphigoid | Double-Blind, Randomized, Placebo-Controlled Trial of AKST4290 for Adjunctive Treatment of Mild to Moderate Bullous Pemphigoid | Pemphigoid, Bullous | Drug: Mometasone furoate;Drug: AKST4290;Drug: Placebo | Alkahest, Inc. | NULL | Recruiting | 60 Years | 95 Years | All | 30 | Phase 2 | Germany |
| 12 | ChiCTR2000029007 | 2020-01-01 | 2020-01-11 | Clinical observation of subclinical dosage of cyclosporine combined with glucocorticoid in the treatment of moderate and severe bullous pemphigoid | Clinical observation of subclinical dosage of cyclosporine combined with glucocorticoid in the treatment of moderate and severe bullous pemphigoid | Bullous Pemphigoid | experimental group:subclinical dosage of Cyclosporine, Prednisone or Methylprednisolone and Halometasone Cream.;control group:Prednisone or Methylprednisolone, Halometasone Cream; | The First Affiliated Hospital of Kunming Medical University | NULL | Recruiting | Both | experimental group:30;control group:30; | Phase 4 | China | ||
| 13 | ChiCTR2000028707 | 2020-01-01 | 2019-12-31 | Randomized, controlled clinical trial for low-dose interleukin-2 in the treatment of moderate to severe bullous pemphigoid | Randomized, controlled clinical trial for low-dose interleukin-2 in the treatment of moderate to severe bullous pemphigoid | Bullous pemphigoid | Moderate BP group 1:Standard treatment plan;Moderate BP group 2:low dose interleukin-2;Severe BP group 1:Standard treatment plan;Severe BP group 2:low dose interleukin-2; | Dermatology Hospital, Southern Medical University | NULL | Recruiting | 12 | 90 | Both | Moderate BP group 1:34;Moderate BP group 2:34;Severe BP group 1:35;Severe BP group 2:35; | China | |
| 14 | NCT03295383 (ClinicalTrials.gov) | July 11, 2019 | 22/9/2017 | Randomized Clinical Trial Comparing the Safety and Efficacy of Rituximab Versus Oral Cyclophosphamide in Severe Forms of Mucous Membrane Pemphigoid | Randomized Double Blind Double Dummy Control Trial Comparing the Safety and Efficacy of Rituximab Versus Oral Cyclophosphamide in Severe Forms of Mucous Membrane Pemphigoid | Severe Forms of Mucous Membrane Pemphigoid | Drug: Rituximab 1g IV;Drug: Cyclophosphamide 50Mg Oral Tablet;Drug: Placebo of Rituximab;Drug: Placebo Oral Tablet | University Hospital, Rouen | NULL | Recruiting | 18 Years | 80 Years | All | 130 | Phase 3 | France |
| 15 | EUCTR2019-001059-37-DE (EUCTR) | 21/06/2019 | 11/06/2019 | Double-Blind, Randomized, Placebo-Controlled Trial of AKST4290 for Adjunctive Treatment of Mild to Moderate Bullous Pemphigoid | Double-Blind, Randomized, Placebo-Controlled Trial of AKST4290 for Adjunctive Treatment of Mild to Moderate Bullous Pemphigoid | Mild to Moderate Bullous Pemphigoid MedDRA version: 21.1;Level: LLT;Classification code 10006567;Term: Bullous pemphigoid;System Organ Class: 100000004858;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Product Name: AKST4290 Product Code: AKST4290 INN or Proposed INN: AKST4290 Other descriptive name: 2-[[[(2R)-1-[1-[(4-CHLORO-3-METHYLPHENYL)METHYL]-4- PIPERIDINYL]-5-OXO-2-PYRROLIDINYL]CARBONYL]AMINO]- N,N,6-TRIMETHYL-4-PYRIDINECARBOXAMIDE,DIHYDROCHLORIDE | Alkahest, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 30 | Phase 2 | Germany | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 16 | EUCTR2018-002564-10-NL (EUCTR) | 23/04/2019 | 23/04/2019 | PDE4 inhibitor (apremilast) in pemphigoid. | Short-term safety, efficacy and mode of action of apremilast in mild to moderate cutaneous pemphigoid: a phase IIa open label single arm study. - SAMP trial | Pemphigoid;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Universitair Medisch Centrum Groningen | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 10 | Phase 2 | Netherlands | |||
| 17 | NCT03926377 (ClinicalTrials.gov) | April 2019 | 15/4/2019 | Influence of Dermocorticoids on Bone Mineral Density in Patients With Bullous Pemphigoid | Influence of Dermocorticoids on Bone Mineral Density in Patients With Bullous Pemphigoid | Osteoporosis;Bullous Pemphigoid | Procedure: bone densitometry;Biological: blood test;Procedure: radiographs of the thoracic and lumbar spine;Procedure: Clobetasol propionate | Centre Hospitalier Universitaire, Amiens | University Hospital, Rouen | Not yet recruiting | 18 Years | N/A | All | 50 | Phase 4 | NULL |
| 18 | NCT04035733 (ClinicalTrials.gov) | September 25, 2018 | 12/4/2019 | rVA576 in Adult Mild to Moderate Bullous Pemphigoid Subjects | A Phase IIa Open-label Single Arm Study of Safety and Efficacy of rVA576 in Adult Mild to Moderate Bullous Pemphigoid Subjects | Bullous Pemphigoid (BP) | Biological: rVA576 | AKARI Therapeutics | NULL | Completed | 18 Years | N/A | All | 9 | Phase 2 | Germany;Netherlands |
| 19 | NCT03636763 (ClinicalTrials.gov) | September 2018 | 16/8/2018 | Dipeptidyl Peptidase-IV Inhibitors, Risk Factor for Development of Bullous Pemphigoid? | Dipeptidyl Peptidase-IV Inhibitors, Risk Factor for Development of Bullous Pemphigoid? : Multicenter Retrospective Study in France and Switzerland | Bullous Pemphigoid | Drug: data report | Assistance Publique Hopitaux De Marseille | NULL | Unknown status | N/A | N/A | All | 183 | France | |
| 20 | ChiCTR1800017560 | 2018-08-31 | 2018-08-04 | Association of serum D-dimer and PDF with the BP severity | Association of serum D-dimer and PDF with the BP severity | Bullous pemphigoid | Gold Standard:Clinical outcome;Index test:D-dimer, FDP, anti-BP180 IgG; | the Second Affiliated Hospital, Xi'an Jiaotong University | NULL | Pending | 18 | 90 | Both | Target condition:160;Difficult condition:0 | China | |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 21 | EUCTR2017-002836-18-DE (EUCTR) | 23/07/2018 | 14/02/2018 | A Clinical study to investigate if rVA576 is safe and has an effect on patients who have mild or moderate Bullous Pemphigoid (a blistering disorder where the skin forms tense blisters) | A Phase IIa open label single arm study of safety and efficacy of rVA576 in adult mild to moderate Bullous Pemphigoid subjects | Mild to Moderate Bullous Pemphigoid MedDRA version: 21.1;Level: LLT;Classification code 10006567;Term: Bullous pemphigoid;System Organ Class: 100000004858;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: rVA576 INN or Proposed INN: rVA576 | Akari Therapeutics Plc. | NULL | Not Recruiting | Female: yes Male: yes | 9 | Phase 2 | Netherlands;Germany | ||
| 22 | EUCTR2018-001417-32-FR (EUCTR) | 13/07/2018 | 11/06/2018 | Long-term Follow-up of patients participants with pemphigus From Study RITUXIMAB3 | Long-term Follow-up of patients participants with pemphigus From Study RITUXIMAB3. Immunological, clinical and medicoeconomic evaluation | Patients with Bullous pemphigoid included in RITUXIMAB3 study MedDRA version: 20.0;Level: LLT;Classification code 10006567;Term: Bullous pemphigoid;System Organ Class: 100000004858;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Trade Name: MABTHERA INN or Proposed INN: RITUXIMAB Trade Name: Prednisone Product Name: CORTANCYL 20 mg INN or Proposed INN: PREDNISONE Other descriptive name: PREDNISONE Trade Name: Prednisone Product Name: CORTANCYL 20 mg INN or Proposed INN: PREDNISONE Other descriptive name: PREDNISONE | CHU-Hôpitaux de Rouen | NULL | Not Recruiting | Female: yes Male: yes | 77 | Phase 3 | France | ||
| 23 | EUCTR2017-002836-18-NL (EUCTR) | 07/05/2018 | 24/01/2018 | A Clinical study to investigate if rVA576 is safe and has an effect on patients who have mild or moderate Bullous Pemphigoid (a blistering disorder where the skin forms tense blisters) | A Phase IIa open label single arm study of safety and efficacy of rVA576 in adult mild to moderate Bullous Pemphigoid subjects | Mild to Moderate Bullous Pemphigoid MedDRA version: 20.0;Level: LLT;Classification code 10006567;Term: Bullous pemphigoid;System Organ Class: 100000004858;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: rVA576 INN or Proposed INN: rVA576 | Akari Therapeutics Plc. | NULL | Not Recruiting | Female: yes Male: yes | 9 | Phase 2 | Germany;Netherlands | ||
| 24 | JPRN-jRCTs051180069 | 12/04/2018 | 19/02/2019 | Imatinib treatment of autoimmune bullous diseases | Intervention study on autoimmune bullous diseases with imatinib - IABD | Autoimmune bullous disease including pemphigus group and pemphigoid group;D012872 | Imatinib 800 mg a day p.o. for seven days will be started within 14 days of starting steroid therapy (and when the bed is secured). Imatinib 800 mg a day p.o. for seven days will be started afterregistered in the trial (and when the bed is secured) in patients with mild symptoms and will not take systemic steroid therapy. | Kabashima Kenji | Endo Yuichiro | Recruiting | >= 20age old | < 100age old | Both | 20 | Japan | |
| 25 | NCT03286582 (ClinicalTrials.gov) | September 5, 2017 | 14/9/2017 | A Proof-of-Concept Study of Topical AC-203 in Patients With Bullous Pemphigoid | A Randomized, Open-Label, Controlled Trial of Topical AC-203 in Subjects With Bullous Pemphigoid | Bullous Pemphigoid | Drug: AC-203 1% Topical Ointment;Drug: Clobetasol 0.05% Topical Ointment | TWi Biotechnology, Inc. | NULL | Terminated | 20 Years | 90 Years | All | 10 | Phase 2 | Taiwan |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 26 | NCT03099538 (ClinicalTrials.gov) | August 15, 2017 | 21/3/2017 | Ixekizumab in the Treatment of Bullous Pemphigoid | Ixekizumab in the Treatment of Bullous Pemphigoid | Bullous Pemphigoid;Pemphigoid | Drug: Ixekizumab | Mayo Clinic | Eli Lilly and Company | Completed | 18 Years | N/A | All | 4 | Phase 2 | United States |
| 27 | NCT02993133 (ClinicalTrials.gov) | December 2016 | 12/12/2016 | Pharmacokinetics Study of Mycophenolic Acid in Patients With an Autoimmune Bullous Dermatose, Pemphigus or Cicatricial Pemphigoid. | Pharmacokinetics Study of Mycophenolic Acid in Patients With an Autoimmune Bullous Dermatose, Pemphigus or Cicatricial Pemphigoid. | Autoimmune Bullous Dermatose | Drug: Cellcept® in autoimmune bullous dermatoses | University Hospital, Limoges | NULL | Completed | 18 Years | N/A | All | 53 | Phase 3 | France |
| 28 | NCT02226146 (ClinicalTrials.gov) | February 2016 | 27/7/2014 | Evaluation of Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Bullous Pemphigoid | An Open-Label, Proof of Concept Study Designed to Evaluate the Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Newly Diagnosed, Moderate to Extensive Bullous Pemphigoid | Pemphigoid, Bullous | Biological: Bertilimumab | Immune Pharmaceuticals | NULL | Completed | 60 Years | N/A | All | 11 | Phase 2 | United States;Israel |
| 29 | NCT02874079 (ClinicalTrials.gov) | December 2015 | 11/8/2016 | Genetic Susceptibility and Influence of the Microbiomae in Bullous Pemphigoid | Genetic Susceptibility and Influence of the Microbiomae in Bullous Pemphigoid | Bullous Pemphigoid | Other: Blood sample and cotton skin swabs | CHU de Reims | NULL | Recruiting | 18 Years | N/A | Both | 100 | N/A | France |
| 30 | NCT02502903 (ClinicalTrials.gov) | July 13, 2015 | 7/7/2015 | Safety, Tolerability and Activity of BIVV009 in Healthy Volunteers and Patients With Complement Mediated Disorders | Safety, Tolerability and Activity of BIVV009 in Healthy Volunteers and Patients With Complement-mediated Disorders. A Single/Multiple Ascending Dose Phase 1 Study. | Bullous Pemphigoid (BP);Cold Agglutinin Disease (CAD);Warm Autoimmune Hemolytic Anemia (WAIHA);End-stage Renal Disease (ESRD) | Drug: BIV009;Other: Placebo | Bioverativ, a Sanofi company | Celerion Clinical Research GmbH;Assign Data Management and Biostatistics GmbH;ABF Pharmaceutical Services GmbH;Quest Diagnostics;Covance Laboratories - Chantilly;PPD Laboratories - Virginia;Softworld Inc. - Cambridge, MA | Active, not recruiting | 18 Years | N/A | All | 122 | Phase 1 | Austria |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 31 | NCT02360202 (ClinicalTrials.gov) | April 2015 | 7/1/2015 | Evaluation of Fluid Retention Due to Superpotent Topical Corticosteroid | Evaluation of Fluid Retention Due to Superpotent Topical Corticosteroid in Patients With Bullous Pemphigoid | Bullous Pemphigoid | Procedure: Impedance analysis;Drug: Clobetasol Propionate cream treatment | University Hospital, Rouen | Société de Dermatologie Française | Recruiting | 18 Years | N/A | All | 35 | Phase 4 | France |
| 32 | NCT02365675 (ClinicalTrials.gov) | January 2015 | 11/2/2015 | Wound Dressings for Pemphigus and Pemphigoid | An Open Randomized Comparative Trial of Four Different Dressings for Cutaneous Coverage in Pemphigus and Pemphigoid | Pemphigus;Pemphigoid | Device: Cotton gauze with petrolatum;Device: Cellulose acetate with petrolatum;Device: Nanocrystalline silver (Acticoat);Device: Carboxymethylcellulose with ionic silver (Aquacel Ag) | Fundación Nacional para la Enseñanza y la Investigación de la Dermatología A.C. | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | Recruiting | 18 Years | N/A | Both | 12 | N/A | Mexico |
| 33 | JPRN-UMIN000015451 | 2014/11/13 | 25/10/2014 | Exploratory research on effectiveness and safety of Rituximab treatment including maintenance administration for steroid intractable autoimmune bullous diseases of the skin.Rtx-BD Trial (Rituximab of Intractable Autoimmune Bullous Disease Trial) 2 | Pemphigus, Pemphigoid | Rituximab 375mg/sqm, q1w, 4 doses. Maintenance administration of rituximab is possible if PDA or BPDAI is between 1 and 10 on week 24 to 48 | Department of Dermatology,Keio University School of Medicine | Hokkaido University, Kurume University, Okayama University, Kawasaki Medical School | Complete: follow-up complete | 20years-old | 80years-old | Male and Female | 20 | Phase 1;Phase 2 | Japan | |
| 34 | NCT02126020 (ClinicalTrials.gov) | November 2014 | 27/4/2014 | Topical Infliximab in Autoimmune Eyes With Keratoprosthesis | Topical Infliximab in Autoimmune Eyes With Keratoprosthesis | Stevens-Johnson Syndrome;Toxic Epidermal Necrolysis (Lyell) Syndrome;Mucous Membrane Pemphigoid | Drug: topical infliximab | James Chodosh, MD, MPH | Massachusetts Eye and Ear Infirmary;Fonds de recherche en ophtalmologie de l'Université de Montréal (FROUM) | Withdrawn | 18 Years | 80 Years | All | 0 | Phase 1;Phase 2 | United States;Canada |
| 35 | JPRN-jRCTs031180220 | 01/05/2014 | 15/03/2019 | Rituximab treatment of blistering disease | Treatment of refractory autoimmuno blistering disease with rituximab | Pemphigus vulgaris, paraneoplastic pemphigus, bullous pemphigoid | Infusion of rituximab (1000mg) intravenously. Approximately two weeks after the first dose, a second dose of rituximab is administered in a similar manner. | Kanaoka Miwa | Michiko Aihara | Not Recruiting | >= 20age old | < 80age old | Both | 10 | N/A | Japan |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 36 | NCT02149732 (ClinicalTrials.gov) | May 2014 | 14/5/2014 | Clinical Trial on the Effect of Autologous Oral Mucosal Epithelial Sheet Transplantation | An Investigator-initiated Trial (IIT) on the Effect of Autologous Oral Mucosal Epithelial Sheet Transplantation in Corneal Limbal Deficiency Patients | Limbal Stem Cell Deficiency;Stevens-johnson Syndrome;Ocular Cicatricial Pemphigoid;Chemical Burn | Biological: cultivated oral mucosal epithelial sheet transplantation | Seoul National University Hospital | Ministry of Health & Welfare, Korea | Available | 16 Years | N/A | Both | Phase 1;Phase 2 | Korea, Republic of | |
| 37 | EUCTR2012-003370-10-FR (EUCTR) | 24/05/2013 | 28/09/2015 | Safety, efficacy and PK/PD of QGE031 vs. placebo in patients with active bullous phemphigoid despite oral steroid treatment. | A randomized, double-blind, placebo controlled, parallel group study evaluating the efficacy, safety, pharmacokinetics and pharmacodynamics of QGE031 in the treatment of patients with bullous pemphigoid with disease refractory to oral steroid treatment | refractory bullous pemphigoid MedDRA version: 18.0;Level: LLT;Classification code 10006567;Term: Bullous pemphigoid;System Organ Class: 100000004858;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Code: QGE031 | Novartis Pharma Services AG | NULL | Not Recruiting | Female: yes Male: yes | 42 | Phase 2 | United States;France;Taiwan;Austria;Germany | ||
| 38 | NCT02837965 (ClinicalTrials.gov) | April 2013 | 24/6/2016 | Observational Study Assessing Outcomes, Treatment Patterns and Related Costs in Patients in Bullous Pemphigoid | Multicenter Prospective Observational Study Assessing Outcomes, Adverse Events, Treatment Patterns and Related Costs in Patients Diagnosed With Bullous Pemphigoid | Bullous Pemphigoid | Drug: treatment with topical superpotent corticosteroid therapy;Drug: treatment with systemic therapy (methotrexate);Drug: treatment systemic therapy (prednisone);Drug: treatment with systemic therapy (prednisone);Drug: treatment with systemic therapy (doxycycline) | CHU de Reims | NULL | Recruiting | 18 Years | N/A | Both | 150 | N/A | France |
| 39 | EUCTR2011-004361-32-DE (EUCTR) | 26/02/2013 | 22/05/2012 | Effect of simvastatin in combination with a superpotent topical corticosteroid in bullous pemphigoid | Effect of simvastatin in combination with a superpotent topical corticosteroid in bullous pemphigoidA prospective multi-centre randomised double-blind placebo-controlled pilot study - SICOPEM | Bullous pemphigoid (BP) is the most frequent blistering autoimmune disease of the skin. The disease itself is characterized by the development of bullous lesions, frequently following a prodromal phase with severe itching. Between 10 to 30 percent of patients exhibit mucosal membrane involvement in addition to the skin lesions.;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Trade Name: Simvastatin-ratiopharm® Product Name: Simvastatin-ratiopharm Other descriptive name: SIMVASTATIN | Philipps-Universität Marburg | NULL | Not Recruiting | Female: yes Male: yes | Germany | ||||
| 40 | NCT01705795 (ClinicalTrials.gov) | February 13, 2013 | 5/10/2012 | Anti-IL-5 Therapy in Bullous Pemphigoid (BP) | Anti-IL-5 Therapy in Bullous Pemphigoid. Randomized, Placebo-controlled, Double-blind Study Evaluating the Effect of Anti-IL-5 Therapy in Patients With Bullous Pemphigoid. | Pemphigoid, Bullous | Drug: Mepolizumab (a-IL-5 antibody);Drug: Placebo | University Hospital Inselspital, Berne | NULL | Completed | 18 Years | N/A | All | 32 | Phase 2 | Switzerland |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 41 | EUCTR2012-003370-10-DE (EUCTR) | 23/01/2013 | 23/10/2012 | Safety, efficacy and PK/PD of QGE031 vs. placebo in patients with active bullous phemphigoid despite oral steroid treatment. | A randomized, double-blind, placebo controlled, parallel group study evaluating the efficacy, safety, pharmacokinetics and pharmacodynamics of QGE031 in the treatment of patients with bullous pemphigoid with disease refractory to oral steroid treatment | Refractory Bullous Pemphigoid MedDRA version: 16.1;Level: LLT;Classification code 10006567;Term: Bullous pemphigoid;System Organ Class: 100000004858;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Code: QGE031 INN or Proposed INN: QGE031 | Novartis Pharma Services AG | NULL | Not Recruiting | Female: yes Male: yes | 42 | United States;Taiwan;Austria;Germany | |||
| 42 | NCT01688882 (ClinicalTrials.gov) | January 2013 | 17/9/2012 | Safety, Efficacy and PK/PD of QGE031 vs. Placebo in Patients With Active Bullous Pemphigoid Despite Oral Steroid Treatment | A Randomized, Double-blind, Placebo Controlled, Parallel Group Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of QGE031 in the Treatment of Patients With Bullous Pemphigoid With Disease Refractory to Oral Steroid Treatment | Bullous Pemphigoid | Drug: QGE031;Drug: Placebo | Novartis Pharmaceuticals | NULL | Terminated | 20 Years | 80 Years | All | 20 | Phase 2 | United States;Austria;France;Germany;Japan;Taiwan |
| 43 | EUCTR2012-003370-10-AT (EUCTR) | 13/11/2012 | 03/10/2012 | Safety, efficacy and PK/PD of QGE031 vs. placebo in patients with active bullous phemphigoid despite oral steroid treatment. | A randomized, double-blind, placebo controlled, parallel group study evaluating the efficacy, safety, pharmacokinetics and pharmacodynamics of QGE031 in the treatment of patients with bullous pemphigoid with disease refractory to oral steroid treatment | Refractory Bullous Pemphigoid MedDRA version: 15.0;Level: LLT;Classification code 10006567;Term: Bullous pemphigoid;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Code: QGE031 | Novartis Pharma AG | NULL | Not Recruiting | Female: yes Male: yes | 42 | United States;Taiwan;Austria;Germany | |||
| 44 | NCT01582880 (ClinicalTrials.gov) | March 2012 | 10/4/2012 | Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis | The Use of Riboflavin/Ultraviolet A Cross-linked Human Donor Corneas as Carriers for the Boston Keratoprosthesis | Chemical Injuries;Unspecified Complication of Corneal Transplant;Autoimmune Diseases;Ocular Cicatricial Pemphigoid;Stevens Johnson Syndrome;Lupus Erythematosus, Systemic;Rheumatoid Arthritis;Other Autoimmune Diseases | Drug: Riboflavin | Joseph B. Ciolino, MD | NULL | Completed | 18 Years | N/A | All | 1 | Phase 1;Phase 2 | United States |
| 45 | NCT02202642 (ClinicalTrials.gov) | January 2012 | 21/4/2011 | The Improvement of Limbal Epithelial Culture Technique by Using Collagenase to Isolate Limbal Stem Cells | The Improvement of Limbal Epithelial Culture Technique for the Treatment of Unilateral Limbal Insufficiency by Using Collagenase to Isolate Limbal Stem Cells | Alkaline Chemical Burn Of Cornea And Conjunctival Sac;Acid Chemical Burn Of Cornea And Conjunctival Sac;Benign Mucous Membrane Pemphigoid With Ocular Involvement | Procedure: collagenase | National Taiwan University Hospital | NULL | Recruiting | 18 Years | 70 Years | Both | 10 | Phase 1 | Taiwan |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 46 | ChiCTR-TRC-12003538 | 2011-08-01 | 2012-12-27 | Use of inravenous Methotrexate plus Glucocorticoid for the Treatment of bullous pemphigoid:A multicenter,randomized and controlled clinincal trial | Guideline-oriented Research in the Management of Some Common and Severe Skin Diseases | Bullous pemphigoid | Glucocorticoids group:This group receives systemic glucocorticoid, initially, with prednisone at 1mg/kg/day. Then we adjust the dose of glucocorticoid according to the patients' responses;Glucocorticoid plus MTX group:This group receives systemic glucocorticoid plus MTX and starts with prednisone at 1mg/kg/day and MTX IV drip infusion at 15mg/week. Then we adjust the dose of glucocorticoid according to the patients' responses.; | Institute of dermatology, Chinese Academy of Medical Sciences | NULL | Recruiting | 18 | 0 | Both | Glucocorticoids group:90;Glucocorticoid plus MTX group:90; | China | |
| 47 | ChiCTR-TRC-12003592 | 2011-08-01 | 2012-12-30 | Use of Tripterygium glycosides and Nicotinamide plus Minocycline for the Treatment of bullous pemphigoid: A multicenter,randomized and controlled clinincal trial | Guideline-oriented Research in the Management of Some Common and Severe Skin Diseases | Bullous pemphigoid | Tripterygium glycosides group:Take tripterygium glycosides orally at 20 mg, 3 times a day;Nicotinamide plus Minocycline group:Take nicotinamide at 500 mg, 3 times a day and minocycline 100 mg, twice a day.; | Institute of dermatology, Chinese Academy of Medical Sciences | NULL | Completed | 18 | Both | Tripterygium glycosides group:100;Nicotinamide plus Minocycline group:100; | China | ||
| 48 | ChiCTR-TRC-12003593 | 2011-08-01 | 2012-12-30 | Use of Oral Methotrexate plus Glucocorticoid for the Treatment of bullous pemphigoid:A multicenter,randomized and controlled clinincal trial | Guideline-oriented Research in the Management of Some Common and Severe Skin Diseases | bullous pemphigoid | Glucocorticoids group:This group receives systemic glucocorticoid, initially, with prednisone at 1mg/kg/day. Then we adjust the dose of glucocorticoid according to the patients' responses.;Glucocorticoid plus MTX group:This group receives systemic glucocorticoid plus MTX and starts with prednisone at 1mg/kg/day and MTX IV drip infusion at 15mg/week. Then we adjust the dose of glucocorticoid according to the patients' responses.; | Institute of dermatology; Chinese Academy of Medical Sciences | NULL | Completed | 18 | Both | Glucocorticoids group:90;Glucocorticoid plus MTX group:90; | China | ||
| 49 | NCT01408550 (ClinicalTrials.gov) | August 2011 | 27/7/2011 | Phase III Clinical Trial of NPB-01 in Patients With Bullous Pemphigoid Unresponsive to Corticosteroids | NPB-01(Intravenous Immunoglobulin) Therapy for Patients With Bullous Pemphigoid Unresponsive to Corticosteroids: Randomized, Double-Blind, Placebo Control,Parallel Assignment Study(Phase III) | Bullous Pemphigoid | Drug: NPB-01;Drug: Placebo | Nihon Pharmaceutical Co., Ltd | NULL | Completed | 20 Years | N/A | Both | 56 | Phase 3 | Japan |
| 50 | NCT01571895 (ClinicalTrials.gov) | July 2011 | 4/4/2012 | Pilot Efficacy and Safety Study of Oral DF2156A in Patients With Active Bullous Pemphigoid | A Phase 2, Multicentre, Single Arm, Pilot Study to Assess the Efficacy and the Safety of 150 mg Twice a Day Oral DF2156A in Patients With Active Bullous Pemphigoid. | Bullous Pemphigoid | Drug: DF2156A | Dompé Farmaceutici S.p.A | NULL | Terminated | 18 Years | N/A | Both | 4 | Phase 2 | Germany;Italy |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 51 | EUCTR2011-000756-42-IT (EUCTR) | 30/06/2011 | 20/03/2012 | pilot phase 2 clinical trial performed in some hospitals to evaluate the efficacy and the adverse events in a group of patients with active bullous pemphigoid that will receive DF2156A at the dose of 150 mg, oral route, twice a day. | A phase 2, multicentre, single arm, pilot study to assess the efficacy and the safety of 150 mg twice a day oral DF2156A in patients with active bullous pemphigoid. - DF2156A in bullous pemphigoid | active bullous pemphigoid MedDRA version: 14.1;Level: LLT;Classification code 10006567;Term: Bullous pemphigoid;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Product Name: NA Product Code: DF2156A INN or Proposed INN: ladarixin | DOMPE' s.p.a. | NULL | Not Recruiting | Female: yes Male: yes | 12 | Phase 2 | Germany;Italy | ||
| 52 | JPRN-UMIN000004428 | 2010/11/01 | 01/11/2010 | Exploratory research on effectiveness and safety of Rituximab treatment for steroid intractable pemphygus, bullous pemphigoid and epidermolysis bullosa acquisita. | pemphigus, bullous pemphigoid, epidermolysis bullosa acquisita | Rituximab | Research group of rare intractable dermatologial disorder | NULL | Complete: follow-up complete | 20years-old | Not applicable | Male and Female | 20 | Phase 2 | Japan | |
| 53 | EUCTR2007-006658-24-DE (EUCTR) | 16/12/2009 | 08/09/2009 | A randomised controlled trial to compare the safety and effectiveness of doxycycline (200 mg/day) with prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid - Bullous Pemphigoid Steroids & Tetracyclines Study | A randomised controlled trial to compare the safety and effectiveness of doxycycline (200 mg/day) with prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid - Bullous Pemphigoid Steroids & Tetracyclines Study | BP is a serious condition with a significant associated morbidity and mortality rate. Widespread tense and haemorrhagic blisters, skin erosions and severe itching cause patients a great deal of distress and pain. It occurs mainly in the elderly. The mortality rate in treated patients is estimated to range from 20% - 40% at one year. MedDRA version: 9.1;Level: LLT;Classification code 10006568;Term: Bullous pemphigoid NOS MedDRA version: 9.1;Classification code 10006567;Term: Bullous pemphigoid | Product Name: prednisolone INN or Proposed INN: prednisolone Product Name: doxycycline INN or Proposed INN: doxycycline | Universitätsklinikum Schleswig-Holstein | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 256 | United Kingdom;Germany | |||
| 54 | ChiCTR-IOR-15007146 | 2009-10-01 | 2015-09-17 | Combined treatment with low dose systemic steroids andtopical steroids in bullous pemphigoid andfactors of treatment-refractory bullous pemphigoid | Efficacy of low dose systemic steroids combined with topical steroids in the treatment of bullous pemphigoid andrisk factors for treatment-refractory patients:A Randomized Controlled Trial | bullous pemphigoid | Control Group (C):apply 0.05% halometasone cream daily;Treatment Group (T):apply 0.05% halometasone cream daily+low-dose systemic steroids; | Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine | NULL | Completed | Both | Control Group (C):40;Treatment Group (T):40; | China | |||
| 55 | EUCTR2007-006658-24-GB (EUCTR) | 05/03/2009 | 22/10/2008 | A randomised controlled trial to compare the safety and effectiveness of doxycycline (200 mg/day) with prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid - Bullous Pemphigoid Steroids & Tetracyclines Study | A randomised controlled trial to compare the safety and effectiveness of doxycycline (200 mg/day) with prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid - Bullous Pemphigoid Steroids & Tetracyclines Study | BP is a serious condition with a significant associated morbidity and mortality rate. Widespread tense and haemorrhagic blisters, skin erosions and severe itching cause patients a great deal of distress and pain. It occurs mainly in the elderly. The mortality rate in treated patients is estimated to range from 20% - 40% at one year. MedDRA version: 14.0;Level: LLT;Classification code 10006568;Term: Bullous pemphigoid NOS;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders MedDRA version: 14.0;Classification code 10006567;Term: Bullous pemphigoid;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders | University of Nottingham | NULL | Not Recruiting | Female: yes Male: yes | 256 | Phase 4 | Germany;United Kingdom | |||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 56 | EUCTR2008-005266-31-FR (EUCTR) | 06/02/2009 | 13/03/2009 | COMPARAISON D'UN TRAITEMENT PAR L'ANTICORPS MONOCLONAL ANTI-CD 20 : RITUXIMAB (MABTHERA®) ASSOCIE A UNE CORTICOTHERAPIE GENERALE COURTE PAR RAPPORT A UNE CORTICOTHERAPIE GENERALE DE LONGUE DUREE CHEZ LES PATIENTS ATTEINTS DE PEMPHIGUS - Rituximab III | COMPARAISON D'UN TRAITEMENT PAR L'ANTICORPS MONOCLONAL ANTI-CD 20 : RITUXIMAB (MABTHERA®) ASSOCIE A UNE CORTICOTHERAPIE GENERALE COURTE PAR RAPPORT A UNE CORTICOTHERAPIE GENERALE DE LONGUE DUREE CHEZ LES PATIENTS ATTEINTS DE PEMPHIGUS - Rituximab III | Pemphogoide bulleuse MedDRA version: 9.1;Level: LLT;Classification code 10006567;Term: Bullous pemphigoid | Trade Name: mabthéra Product Name: mathéra Trade Name: Prednisone Product Name: CORTANCYL 20 mg | CHU-Hôpitaux de Rouen | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | France | ||||
| 57 | NCT00525616 (ClinicalTrials.gov) | December 2008 | 20/7/2007 | Efficiency and Tolerance of Rituximab (mabthéra) in Bullous Pemphigoid | Assessment of Rituximab Efficiency and Tolerance in Treatment of Bullous Pemphigoid. | Bullous Pemphigoid | Drug: Mabthera | University Hospital, Rouen | NULL | Completed | 18 Years | 80 Years | Both | 18 | Phase 3 | France |
| 58 | NCT00809822 (ClinicalTrials.gov) | November 2008 | 11/12/2008 | Clinical Trial of NPB-01 in Patients With Bullous Pemphigoid Unresponsive to Corticosteroids. | NPB-01(Intravenous Immunoglobulin) Therapy for Patients With Bullous Pemphigoid Unresponsive to Corticosteroids: Randomized, Double-Blind, Placebo Control,Parallel Assignment Study(Phase?). | Bullous Pemphigoid | Drug: NPB-01;Drug: Placebo | Nihon Pharmaceutical Co., Ltd | NULL | Completed | 20 Years | N/A | Both | 20 | Phase 2 | Japan |
| 59 | EUCTR2008-000480-41-IT (EUCTR) | 27/05/2008 | 10/06/2008 | Multicenter, randomised, double masked, controlled clinical trial on the safety and efficacy of Cyclosporine A eyedrop treatment on patients with ocular cicatricial pemphigoid. - ND | Multicenter, randomised, double masked, controlled clinical trial on the safety and efficacy of Cyclosporine A eyedrop treatment on patients with ocular cicatricial pemphigoid. - ND | Ocular cicatricial pemphigoid (OCP) MedDRA version: 9.1;Level: LLT;Classification code 10010746;Term: Conjunctivitis chronic | Trade Name: RESTASIS INN or Proposed INN: Cyclosporine | UNIVERSITA' CAMPUS BIOMEDICO | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Italy | ||||
| 60 | NCT02313870 (ClinicalTrials.gov) | January 2008 | 8/12/2014 | Topical Steroids Alone or Associated With Methotrexate in Bullous Pemphigoid | Comparison of Monotherapy With Protracted Superpotent Topical Steroids to Superpotent Topical Steroids Associated With Methotrexate in Bullous Pemphigoid | Bullous Pemphigoid | Drug: clobetasol propionate + Methotrexate;Drug: clobetasol propionate alone | University Hospital, Montpellier | NULL | Recruiting | 18 Years | N/A | Both | 300 | Phase 3 | France |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 61 | EUCTR2007-003545-32-FR (EUCTR) | 14/09/2007 | 23/07/2007 | Etude prospective ouverte de l'efficacité du leflunomide dans le traitement de la pemphigoïde bulleuse en association aux dermocorticoïdes. - ARABUL | Etude prospective ouverte de l'efficacité du leflunomide dans le traitement de la pemphigoïde bulleuse en association aux dermocorticoïdes. - ARABUL | Pemphigoïde bulleuse MedDRA version: 9.1;Level: LLT;Classification code 10006567;Term: Bullous pemphigoid | Trade Name: ARAVA Trade Name: DERMOVAL | CHU de Limoges | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | France | ||||
| 62 | NCT00802243 (ClinicalTrials.gov) | September 2007 | 3/12/2008 | Leflunomide Associated With Topical Corticosteroids for Bullous Pemphigoid | Leflunomide Associated With Topical Corticosteroids for Bullous Pemphigoid. An Open Prospective Study | Bullous Pemphigoid | Drug: leflunomide | University Hospital, Limoges | NULL | Recruiting | 65 Years | N/A | Both | 54 | Phase 2 | France |
| 63 | NCT00472030 (ClinicalTrials.gov) | August 2007 | 8/5/2007 | Efficacy and Safety of Omalizumab in Bullous Pemphigoid | An Open Label Case Series on the Effects of Xolair (Omalizumab) in Bullous Pemphigoid | Bullous Pemphigoid | Drug: Omalizumab;Drug: prednisone | University of Iowa | Genentech, Inc. | Completed | 18 Years | N/A | All | 2 | Phase 4 | United States |
| 64 | NCT00584935 (ClinicalTrials.gov) | January 2006 | 26/12/2007 | Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid | Phase I/II Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid | Ocular Cicatricial Pemphigoid | Drug: Rituximab | University of Alabama at Birmingham | Genentech, Inc.;Biogen | Completed | 19 Years | N/A | All | 3 | Phase 1;Phase 2 | United States |
| 65 | EUCTR2005-001827-12-DE (EUCTR) | 29/12/2005 | 12/07/2005 | Myfortic ® zur Therapie des Bullösen Pemphigoids. Eine offene monozentrische proof-of-concept Studie | Myfortic ® zur Therapie des Bullösen Pemphigoids. Eine offene monozentrische proof-of-concept Studie | Bullous Pemphigoid | Trade Name: Myfortic 180 mg Product Name: Myfortic 180 mg Filmtabletten | Georg-August-Universität Göttingen, Bereich Humanmedizin | NULL | Not Recruiting | Female: yes Male: yes | 10 | Phase 2 | Germany | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 66 | EUCTR2005-002391-14-GB (EUCTR) | 29/09/2005 | 23/08/2005 | Pulsed Intravenous Methylprednisolone for Ocular Pemphigoid- A Pilot Study - IVMP for ocular pemphigoid | Pulsed Intravenous Methylprednisolone for Ocular Pemphigoid- A Pilot Study - IVMP for ocular pemphigoid | ocular mucous membrane pemphigoid | Moorfields Eye Hospital NHS Foundation Trust | NULL | Not Recruiting | Female: yes Male: yes | 20 | Phase 4 | United Kingdom | |||
| 67 | NCT00286325 (ClinicalTrials.gov) | March 2005 | 1/2/2006 | Rituximab in the Treatment of Patients With Bullous Pemphigoid | Rituximab in the Treatment of Patients With Bullous Pemphigoid | Bullous Pemphigoid | Drug: Rituximab | Duke University | Genentech, Inc. | Completed | 18 Years | N/A | All | 8 | Phase 1;Phase 2 | United States |
| 68 | NCT00213421 (ClinicalTrials.gov) | August 2001 | 13/9/2005 | Comparison of Two Therapeutic Strategies of Dermoval in Treatment of Bullous Pemphigus | Bullous Pemphigoid | Drug: Dermoval | University Hospital, Rouen | NULL | Completed | 18 Years | N/A | Both | 330 | France | ||
| 69 | NCT00431119 (ClinicalTrials.gov) | October 1997 | 2/2/2007 | Azathioprine or Mycophenolate Mofetil for Bullous Pemphigoid | A Comparison of Oral Methylprednisolone Plus Azathioprine or Mycophenolate Mofetil for the Treatment of Bullous Pemphigoid | Bullous Pemphigoid | Drug: Azathioprine or Mycophenolate mofetil | University Hospital Muenster | Hoffmann-La Roche | Completed | 18 Years | 90 Years | Both | 70 | Phase 2 | Germany |
| 70 | EUCTR2011-000756-42-DE (EUCTR) | 08/06/2011 | Pilot phase 2 clinical trial performed in some hospitals to evaluate the efficacy and the adverse events in a group of patients with active bullous pemphigoid that will receive DF2156A at the dose of 150 mg, oral route, twice a day. | A phase 2, multicentre, single arm, pilot study to assess the efficacy and the safety of 150 mg twice a day oral DF2156A in patients with active bullous pemphigoid. - DF2156A in patients with active bullous pemphigoid | active bullous pemphigoid MedDRA version: 14.0;Level: LLT;Classification code 10006567;Term: Bullous pemphigoid;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Product Name: not applicable Product Code: DF2156A INN or Proposed INN: ladarixin | Dompé s.p.a. | NULL | Not Recruiting | Female: yes Male: yes | 12 | Phase 2 | Germany;Italy |